Acelyrin (SLRN) Stock Price, News, Quotes-Moomoo

Account Info

Log Out

US Stock MarketDetailed Quotes

SLRN Acelyrin

Watchlist

4.650
-0.040-0.85%

Close Nov 18 16:00 ET

466.51MMarket Cap-1757P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Analysts Offer Insights on Healthcare Companies: ACELYRIN, INC. (SLRN), Cabaletta Bio (CABA) and Mersana Therapeutics (MRSN)
TipRanksNov 15 05:31 ET · Ratings
Morgan Stanley Maintains Acelyrin(SLRN.US) With Hold Rating, Maintains Target Price $6
Moomoo NewsNov 15 05:31 ET · Ratings
Vikram Purohit's Hold Rating on ACELYRIN, INC.: Awaiting Key Data and Trial Progress for Future Stock Movement
TipRanksNov 15 05:30 ET · Ratings
ACELYRIN Is Maintained at Neutral by HC Wainwright & Co.
Dow JonesNov 14 13:42 ET · Ratings
Acelyrin Analyst Ratings
BenzingaNov 14 13:30 ET · Ratings
Acelyrin Shares Are Trading Lower. The Company Reported Q3 Financial Results.
BenzingaNov 14 11:43 ET

Comments

Trytosaveabit

Sep 19 12:15

Not a runner!

$Acelyrin (SLRN.US)$ But sure makes for a nice day! 🥂💵

Trytosaveabit

Sep 19 06:58

News

$Acelyrin (SLRN.US)$ MT Newswires· 2 mins ago
Acelyrin (SLRN) said Thursday that the global late-stage trial of its treatment izokibep in patients with moderate-to-severe hidradenitis suppurativa yielded statistically significant improvement responses across multiple efficacy endpoints.

Jaguar8

Sep 10 06:59

NEWS

$Acelyrin (SLRN.US)$
ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive Surgery
Rapid-fire Oral Presentation to Highlight Efficacy, Safety, and Quality of Life Outcomes
LOS ANGELES, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused ...

Stock Region

Aug 14 12:14

Clinical Biopharmaceutical Company Announces Positive Phase 3 Data

ACELYRIN, INC.: A New Horizon in Immunology.
ACELYRIN, INC. (Nasdaq: SLRN) is a late-stage clinical biopharmaceutical company devoted to accelerating the development and delivery of transformative medicines in the field of immunology. The company is making waves in the medical community with its promising treatments for various immune-related diseases. Founded with a mission to provide life-changing treatment options to patients, ...

Rivera

Aug 13 15:09

Nice

$Acelyrin (SLRN.US)$

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

SLRN Acelyrin

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target